Oncogenic receptor tyrosine kinases are definitive drug therapy targets for the treatment of NSCLC patients containing gene mutations, especially EGFR mutations and ALK rearrangements that are targets of the precision medicine management of chest neoplasms [149,150]. Here, EGFR is linked to non-small cell lung carcinoma.